For more than three years, injectable medications such as Wegovy and Zepbound have helped medical weight loss patients at New Jersey Bariatric Center lose on average 15-20% of their excess body weight
To study whether GLP-1R activation in TNC microglia can alleviate NTG-induced allodynia, the selective GLP-1R agonist liraglutide (800 g/kg, n = 8 per group) and the antagonist exendin(939) (50 g/kg, n = 8 per group) were i.p
Retatrutides pharmacokinetic profile supports a 7-day dosing interval, with steady-state plasma concentrations achieved after approximately 4-5 weeks of consistent dosing
Highlights GLP-1 medicines reduce fat and liver mass more rapidly than skeletal muscle (SKM) Running performance is maintained or improved in mice on GLP-1 medicine GLP-1 medicine modifies the SKM proteome despite similar weight loss as calorie restriction Patients on GLP-1 medicine slightly reduce SKM mass but largely maintain strength Summary The large decrease in body weight with glucagon-like peptide-1 (GLP-1) medicines raises concern about a loss of lean body mass (LBM) and skeletal muscle
The lean-user math uses class analogy from semaglutide and tirzepatide PK literature, not direct retatrutide measurement
Discontinuation rates from the phase 2 trial due to side effects were generally low, though the broader literature on GLP-1 receptor agonists notes that discontinuation rates across the class can reach 20-50% within the first year
